Ardevora Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Ardevora Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$11.5M	Sell	28,349 -26,300	-48%	-$9.72M	1.03%	31
2023 Q3	$19M	Sell	54,649 -52,413	-49%	-$18.3M	0.93%	37
2023 Q2	$37.7M	Sell	107,062 -55,338	-34%	-$18.6M	0.91%	36
2023 Q1	$51.2M	Buy	162,400 +19,500	+14%	+$5.85M	0.92%	51
2022 Q4	$41.3M	Buy	+142,900	New	+$43.6M	0.7%	70

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ardevora Asset Management's VRTX Position: Q4 2023 in Review

Ardevora Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 48% in Q4 2023, selling an estimated $9.72M and leaving 28,349 shares worth $11.5M. The position accounts for 1.03% of the portfolio, ranked #31.

Ardevora Asset Management first reported a position in VRTX in Q4 2022 and has held it in 5 quarters since. The position peaked at $51.2M in Q1 2023. 1,438 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

Ardevora Asset Management held 28,349 shares of Vertex Pharmaceuticals worth $11.5M as of Q4 2023.
Ardevora Asset Management sold 26,300 Vertex Pharmaceuticals shares in Q4 2023, an estimated $9.72M.
Vertex Pharmaceuticals made up 1.03% of Ardevora Asset Management's portfolio in Q4 2023, its #31 holding.
Ardevora Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 5 quarters since.
Ardevora Asset Management's Vertex Pharmaceuticals position peaked at $51.2M in Q1 2023.
1,438 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Ardevora Asset Management's 13F filing for Q4 2023, filed 1 Feb 2024.